ICON offers expertise in the development and management of all aspects of NASH clinical trials

20%-30% of people with non-alcoholic fatty liver disease (NAFLD) gradually progress to Non-Alcoholic Steatohepatitis (NASH) by which stage it is characterised by inflammation and liver damage, including various stages of fibrosis.

NASH is massively under-diagnosed, partly because it is a silent disease with few, often-mild symptoms and partly because definitive diagnosis is by histopathology of a liver biopsy which the treating physician or patient may prefer not to perform and/or provide.

ICON NASH and hepatology experience in the last five years:

  • 49

    Studies conducted
  • 19,600+

    Patients involved
  • 4,088

    Sites worldwide

Our clinical trial experience ranges from the earliest development to the late post-marketing environment, including:

  • NASH experienced project team with proven ability to deliver 
  • NASH therapeutic area expertise 
  • Innovative site selection
  • Focus on recruiting and retaining patients through technology such as FIRECREST
NASH clinical trials

Webinar: Helping NASH study sites to succeed

How can pharma and biotech companies ensure that their NASH trial sites are set up for success and best supported to drive the development of new therapies? Find out in this upcoming webinar.

Register today

ICON provides an extensive range of clinical research solutions, along with deep therapeutic area expertise to help you gain insights into the complexities of NASH.

Strengthened by the robust infrastructure of a full-service CRO and 26 years of experience in clinical research, our NASH-focused offerings can be engaged anywhere in your clinical development pipeline.